$HIMS

‘They Are Thieves’: FTC Complaints About Hims & Hers Detail Surprise Charges

The FTC filed a lawsuit against telehealth company Hims & Hers (Hims & Hers Health, Inc.) alleging it disclosed private health information to third parties and used subscription practices consumers say were misleading. According to the FTC, there were over 4,800 complaints in five years. Complaints cited surprise subscription charges, refund denials, limited medical support, and hard-to-reach support.

Original reporting
Published Aug 7, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 3:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
‘They Are Thieves’: FTC Complaints About Hims & Hers Detail Surprise Charges — source image
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The article highlights alleged consumer harm from surprise subscription charges, difficulty canceling, and alleged lack of meaningful medical support, reinforcing the FTC’s enforcement narrative.

02

Market read

This is a regulatory-risk headline for HIMS, emphasizing alleged unwanted subscription billing and privacy concerns backed by thousands of consumer complaints.

03

What to watch

Traders should watch for any FTC filing specifics (requested remedies, injunction scope), company response, and whether complaint patterns translate into measurable subscription churn or chargebacks.

Relevance 7/10Novelty 6/10Timing: today’s report on FTC complaint volume and allegations

Background

The FTC filed a lawsuit against Hims & Hers alleging privacy violations and problematic subscription practices; Gizmodo used FOIA to obtain complaint data.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

FTC lawsuit and FOIA complaint patterns allege Hims & Hers disclosed private health data and used unwanted subscription billing.

Expected impact

Near-term downside bias on enforcement headlines; magnitude depends on lawsuit details and any follow-on FTC actions.

Evidence & confidence

The article centers on an FTC lawsuit and thousands of related complaints, which can drive risk repricing even without new financial guidance or a disclosed settlement.

Market effects

Raises scrutiny on telehealth subscription and negative-option billing practices, potentially increasing compliance costs across the category.

Primarily US regulatory and consumer-protection impact.

US enforcement could spill over to other jurisdictions’ regulators and consumer-billing standards.

Counterpoint

Hims & Hers may dispute the allegations, and the FOIA complaint set is not adjudicated evidence, so market impact could fade if FTC case details are weak.

Key entities

  • Hims & Hers

    Telehealth company accused by the FTC of privacy and subscription-billing misconduct; subject of the lawsuit and complaint patterns.

  • FTC

    US Federal Trade Commission, which filed the lawsuit and provided complaint-volume context via FOIA.

  • Gizmodo

    Published FOIA-derived complaint excerpts and reported the FTC complaint count and redaction limits.

Related articles

$HIMSHighAI 9/10

FTC Sues Hims & Hers Over Health Privacy and Billing Practices

The U.S. FTC sued telehealth company Hims & Hers, joined by California and Utah, alleging it shared consumers’ private health data with ad platforms owned by Meta and Snap and billed some customers for prescriptions without meaningful consultation. The FTC also alleges unclear refill and subscription cancellation practices. Hims said its privacy policy lets patients choose data use; its stock fell nearly 12% on Wednesday.

$HIMSMedAI 8/10

As GLP-1s Transform Telehealth, the FTC Takes Aim at Hims

The FTC, according to its July 29 complaint, is suing Hims & Hers Health over alleged deceptive practices in telehealth subscription enrollment and privacy. The FTC claims consumers were charged for automatically renewing prescription subscriptions without informed consent, faced unclear refill timing and difficult cancellation, and were misled about how sensitive data was handled. The FTC seeks injunctions and monetary remedies.

$HIMSMed

HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform

Hims & Hers Health (HIMS) said it added eight partners to its Hims & Hers Benefits program, covering fitness, nutrition, preventive health and glucose monitoring. It integrated Dexcom’s Stelo with discounts passed to subscribers. HIMS shares rose about 1% and analysts at BofA cut its price target to $25. For 2026, Hims forecasts $2.8B to $3.0B revenue and $275M to $350M EBITDA.

$HIMSMed

Hinge Health, Inc. Q2 2026 Earnings Call Summary

Hinge Health reported Q2 2026 revenue up 53% year over year, citing higher yield from targeted enrollment and referrals. Operating margin rose 1,000 bps to 29%. Full-year 2026 revenue guidance increased to $856 million-$860 million. Hinge plans to expand beyond MSK via a $105 million acquisition of Cylinder Health, expected to add $7 million-$8 million in 2026 revenue and lift margins over 1-2 years.

$HIMSMed

HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Kirby McInerney LLP said it is investigating potential securities-fraud claims against Hims & Hers Health, Inc. (NYSE: HIMS). The probe follows an FTC lawsuit filed July 29, 2026 alleging Hims shared customers’ medical information with third-party advertisers, including Meta Platforms. After the news, Hims shares fell $4.32, or 14.73%, to $25.00.

$HIMSMedAI 8/10

FTC Sues Hims & Hers Over Health Data, Subscription Claims

The FTC, Utah, and Los Angeles County sued Hims & Hers Health Inc., alleging the telehealth provider shared patients’ sensitive health data with ad platforms such as Meta and Snap while claiming privacy protections. Regulators also allege deceptive billing and subscription practices, including charges after intake forms and unclear cancellation timing. The case is pending in federal court.